A working vocabulary for high-stakes questions

Ibogaine Glossary

Key terms defined for clinicians, researchers, patients, families, and policymakers seeking careful language around an experimental substance and its risks.

Quiet clinical research setting supporting careful discussion of ibogaine terminology

Statement

Definitions should make uncertainty clearer, not smaller.

This glossary is a reference for discussing ibogaine without treating specialized language as a substitute for evidence, medical judgment, legal advice, or informed consent. For broader context, Kithara’s independent ibogaine resource sets out the same cautious, evidence-first approach.

Terms are concise by design. Each entry states what a term means, why it matters to safety or efficacy discussions, and where to look next inside the glossary.

Pharmacology

Names for compounds, receptors, metabolism, and cardiac ion channels help distinguish a proposed mechanism from a demonstrated clinical outcome.

Clinical language

Withdrawal, screening, monitoring, and dosing terms describe processes that require individualized assessment rather than a universal protocol.

III

Governance & ethics

Regulatory status, research pathways, and consent vocabulary clarify what oversight exists—and what it does not establish.

Pillar I

Pharmacology & metabolism

Pharmacology can describe biological interactions, but it does not itself prove benefit or predict individual outcomes. The explanation of how ibogaine works should therefore be read alongside the limits of the available evidence.

Ibogaine is a naturally occurring psychoactive alkaloid associated with plants in the Apocynaceae plant family. Its effects and risks involve multiple systems, making simple one-receptor explanations incomplete.

Alkaloid

A naturally occurring nitrogen-containing compound, often biologically active. Ibogaine is classified as an indole alkaloid; the label describes chemistry, not safety or therapeutic value.

Bioavailability

The proportion of a dose that reaches systemic circulation. Route, metabolism, and individual variation can affect exposure, so nominal dose alone cannot define risk.

See also: First-pass metabolism · Pharmacokinetics

CYP metabolism

Drug processing mediated by cytochrome P450 enzymes. CYP2D6 is commonly discussed with ibogaine because metabolic differences and interacting medicines may alter exposure.

See also: CYP2D6 · Drug–drug interaction

CYP2D6

A cytochrome P450 enzyme involved in metabolism of many medicines and in conversion of ibogaine to noribogaine. Genetic variation and inhibitors can matter when assessing exposure.

Drug–drug interaction

A change in effect or exposure caused by another substance. Interactions can involve metabolism, additive sedation, or cardiac electrical effects and require careful review.

See also: CYP metabolism · QTc prolongation

First-pass metabolism

Metabolism that occurs in the gut and liver before an orally administered compound enters wider circulation. It contributes to variability between a swallowed dose and measured exposure.

See also: Bioavailability · Noribogaine

hERG

Short for the human ether-à-go-go-related gene, which encodes a potassium channel important in cardiac repolarization. hERG-channel effects matter because delayed repolarization can be associated with QT prolongation.

Half-life

The time it takes for a measured concentration to decrease by half under stated conditions. It is a pharmacokinetic estimate, not a stand-alone guide to when risk has ended.

See also: Pharmacokinetics · Noribogaine

Ibogaine

A psychoactive indole alkaloid. It is discussed in relation to substance-use treatment claims, but it carries serious potential risks and is not FDA-approved as a treatment.

Metabolite

A compound produced when the body processes another compound. Metabolites may have their own biological activity, duration, and safety implications.

Noribogaine

A major metabolite of ibogaine. It is frequently considered in discussions of duration and mechanism because it may remain present after the parent compound declines.

Pharmacodynamics

The study of what a compound does to the body, including receptor and channel effects. It should not be confused with evidence that an intervention is clinically effective.

Pharmacokinetics

The study of absorption, distribution, metabolism, and elimination. These concepts help explain why concentration and timing can differ across people.

Receptor

A cellular protein that can respond to a chemical signal. Receptor activity is a mechanistic observation and does not independently establish a treatment outcome.

Tabernanthe iboga

A shrub native to Central Africa whose root bark is a traditional source associated with iboga alkaloids. Plant origin does not make a preparation standardized or inherently safe.

Transporter

A protein that moves substances across cell membranes. Transporter interactions are part of pharmacology discussions, but their clinical significance can depend on dose and context.

See also: Pharmacodynamics · Drug–drug interaction

Pillar II

Clinical concepts & safety language

“A term can identify a risk without telling anyone how likely it is for a particular person.”

Clinical vocabulary helps make questions more precise: what is being assessed, what is being monitored, and what remains uncertain. It does not replace a qualified medical evaluation. The U.S. Food and Drug Administration’s guidance on drug-induced QTc prolongation explains why cardiac electrical effects are taken seriously in medicine-development settings.

People evaluating claims about ibogaine treatment for addiction may encounter these terms frequently; their presence should prompt questions about screening, exclusions, monitoring, and evidence quality.

Measured research environment reflecting the importance of safety terminology and monitoring

Adverse event

An unwanted medical occurrence after an intervention or exposure, whether or not causation is established. Recording events is central to safety assessment.

See also: Serious adverse event · Causality

Baseline assessment

Information collected before an intervention, such as medical history, current medicines, and relevant tests. It provides context for risk assessment and later observations.

See also: Screening · Medication reconciliation

Cardiac monitoring

Observation of heart rhythm or related measures using clinical equipment. It matters where arrhythmia risk is a concern, but monitoring itself does not eliminate risk.

Contraindication

A condition or circumstance in which a drug or procedure should not be used because risk may outweigh potential benefit. It is context-specific and requires assessment.

See also: Screening · Risk–benefit assessment

Dosing paradigm

A structured approach describing amount, timing, route, and related observation. A paradigm is not a guarantee of safety and should not be treated as a self-use instruction.

ECG

Electrocardiogram, a recording of the heart’s electrical activity. ECGs are used to assess rhythm and intervals, including QT and QTc.

Medication reconciliation

A structured review of prescribed medicines, over-the-counter products, and other substances. It matters because unrecognized interactions can alter risk.

See also: Drug–drug interaction · Screening

Opioid use disorder

A diagnosable pattern of opioid use associated with clinically significant impairment or distress. It is a specific clinical term and should not be used as a shorthand for every opioid-related experience.

QT interval

An ECG measurement from the start of ventricular depolarization to the end of repolarization. Interpretation depends on clinical context and heart rate.

QTc

A heart-rate-corrected QT interval. Prolongation can be associated with heightened risk of certain arrhythmias, which is why it appears in cardiac safety discussions.

Screening

A process of identifying factors that may affect eligibility or risk, such as health conditions, medicines, and substance use. Its quality depends on what is assessed and how findings are acted on.

See also: Baseline assessment · Contraindication

Serious adverse event

An adverse event meeting defined seriousness criteria, such as death, life-threatening experience, hospitalization, disability, or congenital anomaly. Seriousness differs from intensity.

See also: Adverse event · Safety signal

Torsades de pointes

A potentially dangerous form of ventricular tachycardia associated with prolonged repolarization. The term matters because QTc prolongation is evaluated partly in relation to this risk.

Withdrawal

A set of symptoms that may occur when substance use is reduced or stopped after physiological adaptation. Timing and severity vary by substance and person.

See also: Opioid use disorder · Acute care

Arrhythmia

An abnormal heart rhythm. The term is broad and does not identify a cause; context, ECG findings, and clinical evaluation matter.

See also: Cardiac monitoring · Torsades de pointes

Risk–benefit assessment

A structured comparison of possible harms, anticipated benefits, alternatives, and uncertainty. It should be individualized and revisited when circumstances change.

See also: Informed consent · Contraindication

Pillar III

Regulation, research & ethics

Legal status varies by jurisdiction and can change. In the United States, ibogaine is listed in Schedule I under the Controlled Substances Act; the DEA’s drug scheduling overview describes the federal scheduling framework.

Descriptions of programs outside the United States, including an ibogaine Mexico retreat or an ibogaine clinic in Tijuana, should never be treated as proof of clinical quality, licensing, safety, or regulatory equivalence.

Compassionate use

A term often used for pathways that may provide access to an investigational medical product outside a clinical trial under defined conditions. It is jurisdiction-specific and should not be used as a general synonym for availability. See also: Expanded access · IND

Data Safety Monitoring Board

An independent group that may review accumulating trial data for participant safety and study conduct. Not every study has one; its role depends on the protocol. See also: Clinical trial · Protocol

Equipoise

Genuine uncertainty within the expert community about which intervention is preferable. It is an ethical concept used when considering whether a comparative study is justified. See also: Clinical trial · Informed consent

Expanded access

A regulated route sometimes called compassionate use in the United States for access to investigational products outside trials. Its existence does not establish approval, effectiveness, or routine availability. See also: IND · Compassionate use

Good Clinical Practice

An international ethical and scientific quality standard for designing and conducting clinical research involving human participants. It supports credible data and participant rights. See also: Protocol · Informed consent

IND

Investigational New Drug application, a U.S. regulatory mechanism that allows a sponsor to propose clinical investigation of a drug not approved for marketing. An IND is not marketing approval. See also: Clinical trial · FDA approval

Informed consent

An ongoing process of communicating material information, uncertainty, alternatives, and voluntary choice. A signature alone does not establish that consent was informed. See also: Capacity · Undue influence

Institutional Review Board

A committee that reviews certain human-subjects research to protect participant rights and welfare. Review does not guarantee that a study will benefit a participant. See also: Protocol · Informed consent

Protocol

A written research plan covering objectives, methods, eligibility, procedures, and oversight. A protocol supports consistency but cannot remove uncertainty or all foreseeable risk. See also: Clinical trial · Data Safety Monitoring Board

Scheduling

A legal classification system for controlled substances. Schedule placement is a legal status and should not be conflated with a complete scientific account of harms or potential utility. See also: Controlled substance · IND

Undue influence

Pressure or inducement that may compromise a voluntary decision. It matters especially when people are distressed, in withdrawal, financially vulnerable, or facing limited options. See also: Informed consent · Capacity

Vulnerable population

A group that may need additional safeguards in research because the ability to protect its own interests can be limited. The term calls for care, not stereotyping. See also: Informed consent · Institutional Review Board

Evidence terms

How claims are described matters.

Coverage of current ibogaine developments can introduce new terminology quickly. The terms below help separate a research observation from a conclusion about safety or efficacy.

Blinding

A method that withholds treatment assignment from participants, investigators, or assessors when feasible. It can reduce certain biases but is not possible in every design.

Clinical trial

A planned study involving human participants designed to answer specific research questions. Trial participation and regulatory approval are different concepts.

Confounding

A distortion in which another factor is associated with both an exposure and outcome. It can make a result appear stronger, weaker, or different from the underlying relationship.

Control group

A comparison group used to help interpret outcomes. The type of control affects what a study can reasonably show.

Efficacy

The effect of an intervention under specified study conditions. It differs from effectiveness in ordinary practice and does not by itself settle safety questions.

Endpoint

A predefined outcome used to assess a study question. Whether an endpoint is meaningful depends on its definition, measurement, timeframe, and relevance.

Evidence quality

An appraisal of how much confidence a body of research warrants. Design limitations, bias, precision, consistency, and applicability can all affect confidence.

See also: Systematic review · Replication

Generalizability

The extent to which study findings may apply beyond the participants and setting studied. Strict exclusions can improve internal control while limiting generalizability.

See also: External validity · Eligibility criteria

Observational study

A study that observes exposures and outcomes without assigning an intervention. It can identify patterns but is particularly vulnerable to confounding.

Placebo

An inactive or comparison intervention used in some studies. Placebo-controlled designs can aid interpretation, but ethics and feasibility depend on the condition and alternatives.

Randomization

Assignment by chance to study groups. When properly implemented, it helps balance known and unknown differences between groups.

Replication

Repeating research to see whether results hold under similar or different conditions. A single study, especially a small one, rarely settles a complex clinical question.

See also: Evidence quality · Systematic review

Safety signal

Information suggesting a possible causal association or new aspect of a known association that warrants further assessment. A signal is not proof of causation.

See also: Adverse event · Pharmacovigilance

Systematic review

A structured synthesis of research that uses stated methods to identify, appraise, and summarize studies. Its conclusions are limited by the quality and comparability of included evidence.

See also: Evidence quality · Meta-analysis

Therapeutic claim

A statement that an intervention treats, prevents, cures, or mitigates a condition. Claims should be evaluated against the evidence and applicable regulatory rules.

Validity

The extent to which a study or measure supports the conclusion drawn from it. Internal validity concerns the study itself; external validity concerns applicability elsewhere.

A few terms that are commonly misunderstood

Some phrases carry more certainty in everyday speech than they warrant in clinical, scientific, or legal contexts. The following distinctions are useful starting points.

Is ibogaine approved as a treatment in the United States?

Ibogaine is not approved by the U.S. Food and Drug Administration as a treatment. U.S. research involving a controlled investigational drug generally requires an Investigational New Drug application and institutional oversight.

Why do QTc and hERG appear in ibogaine discussions?

Both terms concern cardiac electrical risk. QTc is a rate-corrected ECG measure, while hERG refers to a potassium-channel mechanism associated with delayed cardiac repolarization and, in some circumstances, torsades de pointes.

Does “natural” describe a safety profile?

No. “Natural” describes origin, not dose, purity, interactions, pharmacology, or clinical risk. It cannot substitute for evidence, screening, or monitoring.

Does a study term prove a treatment claim?

No. A mechanism, case series, observational study, or trial result each answers different questions and has different limits. For a broader discussion of claimed ibogaine therapy benefits, distinguish the wording of a claim from the strength of supporting evidence.

A careful next step

Keep definitions connected to the questions that matter.

When assessing programs or claims, use precise terms to ask about evidence, oversight, safety precautions, and legal context. Comparative directories such as top ibogaine treatment centers are not a substitute for independent due diligence or professional advice.

Kithara — evidence before claims

Review safety & risk terms